Where does Imascap SAS rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Imascap SAS ranks #35,827 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Imascap SAS hold?

Imascap SAS holds 7 US utility patents granted between 2020 and 2023, spanning 5 technology areas.

What is Imascap SAS's Innovation Score?

Imascap SAS has an Innovation Score of 28.8 out of 100 (28th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Imascap SAS's patent grant rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for Imascap SAS.

What does claim depth mean for Imascap SAS's patents?

Imascap SAS's patents average 14.4 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Imascap SAS patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Imascap SAS

Q: What technology areas does Imascap SAS focus on?

Imascap SAS's top technology area is A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive DEVICES; FOMENTATION; Treatment OR Protection OF Eyes OR EARS; Bandages, Dressings OR Absorbent PADS; Firs) with 7 patents. Grants appear in 5 CPC subclasses total.

USPTO PatentsView assignee record - 7 granted patents across 5 technology areas, recorded in grant years 2020–2023. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive Device).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Imascap ranks #35,827 of 49,997 tracked US assignees by granted-patent volume, with 7 patents across 5 technology areas.

#35,827
of 49,997 US assignees by volume: 28th percentile
by Innovation Score (28.8/100): 14.4
avg claims per patent

USPTO PatentsView assignee plate

Corpus R35827 · Foreign Corporation #35,827 · 7 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · SPAN-YRS · BOOK-RICH

GRANTS-MICRO 7 grants
MID-PACK #35,827/49,997
PHOTO-FINISH ILC Dover IP
CPC-NARROW A61F · 5 areas
INNOV-THIN 28.8/100
CLAIMS-RICH 14.4 claims/avg
TYPE-FRNCORP Foreign Corp
SPAN-YRS 2020–2023 · 4y
BOOK-RICH 9/10 fields

Nearest grant-volume peer: ILC Dover IP, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Imascap SAS · this assignee

29
3D Lighting… · lowest

7

What this shows Imascap's Innovation Score is 28.8/100 (28th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where Imascap's grants concentrate

Imascap SAS is a focused PatentsView assignee: 5 CPC subclasses with 100% of grants classified under A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive Device). Peak complete grant year is 2020 (2 grants) versus a trough of 1 in 2022. By volume, Imascap sits between ILC Dover IP, Inc. and Immobiliare Metalprogetti S.R.L..

Imascap's three-year grant acceleration

Imascap SAS shows 3 grants in 2022–2024 against only 4 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

ILC Dover IP

7
ILC Dover

7
Image Insight

7
Imagilin Technolo…

7
Imec USA Nanoelec…

7
Imgt

7
IMI Systems

7
Immobiliare Metal…

7
Imascap SAS ◀

7

What this shows Imascap holds 7 patents at rank #35,801, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Imascap

By rank, the assignees closest to #35,801 in granted patent volume.

Leaders in A61F (Filters Implantable Into Blood Vessels)

Other assignees with the most granted patents in Imascap's primary technology class.

Imascap's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

29 28th percentile higher than 28% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2020–2023

Grants by year

Teal-shaded recent years (2020–present) versus the 2020–2019 baseline. Full figures in the table below.

View data table

Imascap SAS patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2020	2	28.6%
2021	2	28.6%
2022	1	14.3%
2023	2	28.6%

Which technologies does Imascap SAS patent most?

A61F - Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive DEVICES; FOMENTATION; Treatment OR Protection OF Eyes OR EARS; Bandages, Dressings OR Absorbent PADS; Firs 7

A61B - DIAGNOSIS; SURGERY; Identification 6

G16H - Healthcare Informatics, i.e. Information AND Communication Technology [ICT] Specially Adapted FOR THE Handling OR Processing OF Medical OR Healthcare Data 3

G06F - Electric Digital Data Processing 2

B33Y - Additive Manufacturing, i.e. Manufacturing OF Three-dimensional [3-D] Objects BY Additive Deposition, Additive Agglomeration OR Additive Layering, e.g. BY 3-D Printing, Stereolithography OR Selective Laser Sintering 1

Top 5 of 5 technology areas

Where it ranks

Overall rank by patents

#35,827

of 49,997 tracked assignees

Innovation Score

28.8 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Imascap SAS's patent record in context - here's where to go next.

Imascap SAS's lead technology class is A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive Device), 100% of its portfolio - see every assignee active in that class. Explore A61F
Ranked #35,827 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Imascap SAS against ILC Dover IP, Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 28.8/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.